ArticleFrontiers in immunology2026
EV-derived miR-1246 promotes lymph node metastasis in esophageal squamous cell carcinoma through targeting the PPP2CB/NF-κB axis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lymph node metastasis (LNM) is a critical factor contributing to poor prognosis in esophageal squamous cell carcinoma (ESCC) patients. Consequently, elucidating its molecular mechanisms and identifying effective therapeutic targets have become a paramount challenge in clinical practice. Methods: Plasma samples were systematically collected from healthy individuals, ESCC patients without LNM, and those with LNM. Extracellular vesicles (EVs) were isolated from plasma by size-exclusion chromatography (SEC) and ultracentrifugation (UC) methods, and EV-derived miRNA expression profiles were detected and compared by sequencing. Differentially expressed miR-1246 was selected, and a diagnostic model based on plasma EV-miR-1246 was established to predict LNM. The biological functions of EV-miR-1246 and its target gene PPP2CB, which was identified by mass spectrometry combined with online target prediction methods, in the LNM of ESCC were further investigated using Results: MiR-1246 levels were significantly elevated in plasma extracellular vesicles from ESCC patients with lymph node metastasis. The diagnostic model established based on vesicular miR-1246 showed favorable predictive efficacy for lymph node metastasis status in ESCC. Conclusions: This study demonstrates that EV-derived miR-1246 acts as a promising predictive biomarker for lymph-node metastasis in ESCC. Mechanistically, EV-delivered miR-1246 targets PPP2CB to activate NF-κB signaling, thereby driving lymphatic endothelial activation and lymph node metastasis. These findings offer novel diagnostic biomarkers and therapeutic targets for ESCC patients with lymph node metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.